Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly. It is sold under two FDA-approved brand names: Mounjaro for type 2 diabetes management and Zepbound for chronic weight management in adults with obesity or overweight accompanied by at least one weight-related comorbidity. In the SURMOUNT-1 clinical trial, participants using the 15 mg weekly dose lost a mean of 22.5 percent of body weight over 72 weeks, a result that outpaced all previously approved anti-obesity medications. Because tirzepatide carries a boxed warning for thyroid C-cell tumors observed in rodent studies, along with clinically significant risks of pancreatitis and gallbladder disease, it requires a valid prescription from a licensed medical provider. Any website advertising tirzepatide for sale without requiring a valid prescription is operating outside U.S. law, and products from those sources cannot be verified for sterility, concentration accuracy, or authentic origin.
The traditional route to a prescription runs through an endocrinologist, obesity medicine specialist, or primary care physician. Standard qualifying criteria include a body mass index of 30 or higher, or a BMI of 27 or above combined with at least one comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnea. Prescribers will also screen for contraindications, particularly a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Telehealth platforms have made access significantly faster. Services like Ro, Found, and Hims and Hers Health offer video or asynchronous consultations that can produce a prescription within 24 to 48 hours, typically bundled with lab coordination, dosing titration support, and monthly clinical check-ins. Patients should verify that the telehealth prescriber holds an active license in their home state and that the platform clearly discloses whether it dispenses branded or compounded product before completing any consultation or payment.
The most reliable places to find branded tirzepatide for sale are licensed retail pharmacies operating under a valid state board of pharmacy registration. Mounjaro and Zepbound auto-injector pens are stocked at most major chains, including CVS, Walgreens, Rite Aid, and Costco Pharmacy, as well as through mail-order services like Express Scripts and OptumRx. Cash prices without insurance typically range from $1,060 to $1,100 per four-pen monthly carton at Eli Lilly's list price. Eli Lilly offers the Mounjaro Savings Card and the Zepbound Savings Card, which can reduce out-of-pocket costs to as little as $25 per month for eligible commercially insured patients. Both programs explicitly exclude Medicare and Medicaid beneficiaries, so federally insured patients will need to explore alternative coverage pathways.
When Mounjaro and Zepbound appeared on the FDA's drug shortage list between 2022 and 2024, federal regulations permitted state-licensed 503A compounding pharmacies and federally registered 503B outsourcing facilities to produce tirzepatide base and its salts as a legal alternative. Many patients seeking tirzepatide for sale turned to these compounders, which often offered monthly supplies at $150 to $350 — a fraction of the branded list price. In early 2025, the FDA removed tirzepatide from the shortage list, eliminating the legal basis for most compounded versions. By mid-2025, the majority of compounded tirzepatide being sold online is either operating in a prohibited gray area or is outright illegal. Patients who used compounded product during the shortage period should speak with their prescriber about transitioning to branded pens. Counterfeit and mislabeled products marketed as peptide research chemicals have been seized by the FDA and found to contain incorrect active concentrations, bacterial contamination, or entirely different compounds.
Coverage for tirzepatide varies significantly by indication and plan type. Mounjaro, approved for type 2 diabetes, is covered by a broader share of commercial plans than Zepbound, which carries an obesity-only indication. Most insurers that do cover Zepbound require prior authorization documenting the patient's current BMI, a qualifying comorbidity, and evidence of a prior structured weight-loss attempt. Medicare Part D does not cover anti-obesity medications by statute, though select Medicare Advantage plans have begun offering partial coverage as a supplemental benefit. Patients appealing a coverage denial should obtain a letter of medical necessity from their prescriber and submit supporting clinical notes alongside the insurer's prior-authorization criteria checklist, since first-level appeals are granted more frequently when documentation is complete at submission.
If you are looking for the next generation of weight loss peptides, Tirzepatide 5mg is the industry leader. While semaglutide only targets the GLP-1 receptor, Tirzepatide adds the power of GIP, which enhances fat metabolism and improves insulin sensitivity. The 5mg dosage is a po
When comparing Semaglutide vs Tirzepatide, the 10mg dosage of Tirzepatide clearly demonstrates why dual-agonists are the future of weight loss. At this concentration, Tirzepatide consistently outperforms single-agonist peptides in both total body weight reduction and improvements
If you have titrated through the lower doses and found your weight loss stalling, Tirzepatide 15mg is the definitive plateau buster. This maximum dose provides the biological leverage needed to crush metabolic adaptation—the process where your body slows its metabolism to cling t
Obesity and metabolic syndrome require a long-term strategy, and our Tirzepatide 30mg vial provides the sustained support you need. This high-capacity vial is ideal for users transitioning through the middle tiers of the tirzepatide dosage chart, such as a full month's supply of
When comparing oral weight loss medications, the debate of oral semaglutide vs oral tirzepatide has a clear winner. While semaglutide tablets only activate the GLP-1 receptor, oral tirzepatide harnesses the synergistic power of both GIP and GLP-1. This dual-agonist approach drive
When comparing oral weight loss medications, the debate of semaglutide vs tirzepatide tablets has a clear winner. While oral semaglutide only activates the GLP-1 receptor, Tirzepatide tablets harness the synergistic power of both GIP and GLP-1. This dual-agonist approach drives s
Compare prices, purity and shipping at a glance.